The Binding Site

Timely diagnosis of Multiple Myeloma is crucial for effective treatment and improved outcomes. Early detection can lead to more targeted therapies, better management of symptoms, and potentially higher survival rates. Earlier diagnosis and therefore commencement of treatment significantly improves 5-year survival rates of patients. Check out our graphic below for more information on why a timely diagnosis important. https://lnkd.in/eD6b7aYH #MultipleMyeloma #Diagnosis

Join us at the 22nd National Congress of the GSCC-CB in collaboration with the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Scientific Division, where there will be joint meeting on Mass Spectrometry in the Clinical Laboratory. During which you will have the opportunity to hear from Dr. Katie Horton (PhD), Medical Scientific Liaison Specialist, on the Binding Site's latest innovation for Monoclonal Gammopathy the EXENT® System. https://eekx-kb.gr/22pskx/ #Innovation #Multiplemyeloma #EXENTSystem

Professor Andrew Spencer underscores the significance of prompt referral to specialized care for individuals suspected of having Myeloma. The complex nature of modern cancer treatment necessitates swift access to an appropriate specialist. Patients with elevated serum free light chain levels in initial tests may be at risk of developing incipient renal failure, which can rapidly deteriorate to advanced stages if not addressed promptly. To learn more about when should a GP refer a patient to a haematologist upon receiving abnormal results, watch our video.

Register now to attend this webinar with Myeloma UK Join Dr Brogan Ashley, Head of Research & Early Diagnosis at Myeloma UK as she discusses the importance of diagnosing Myeloma in a timely manner and how laboratories play a key role in the diagnosis pathway. Register here: https://hubs.li/Q02VQ2930

In a recent issue of Blood, a publication from T. Kubicki et al. highlighted that the EXENT® System provides significant prognostic information in the maintenance setting and complements bone marrow MRD assays in Multiple Myeloma. Read the article here: https://hubs.li/Q02Vg_Xx0 The EXENT System integrates an immunoassay with MALDI-ToF mass spectrometry to provide a sensitive and specific tool for the measurement of M-proteins throughout the patient pathway.

Discover our transformative solution! The EXENT® System is our latest innovation for monoclonal gammopathy assessment. Register for a live demonstration here: https://hubs.li/Q02V8Qxq0 #Innovation #Multiplemyeloma #Monoclonalgammopathy

Unlike some other cancers, Myeloma can present with various and vague indications. Multiple Myeloma most frequently affects people over 60 years of age and common presenting symptoms can often be associated with the natural aging process. In this clip, Professor Andrew Spencer provides insight into some common symptoms to help Primary Care Providers recognize the signs of Multiple Myeloma, helping them in effective early diagnoses. Learn more about Multiple Myeloma diagnosis criteria for primary care providers: https://hubs.li/Q02TWM6t0 #MultipleMyeloma #Diagnosis

The journey towards diagnosing Multiple Myeloma, a cancer of the bone marrow, can often be complex, primarily due to the non-specific and heterogenous presenting symptoms of this insidious disease. We had the privilege of sitting down with Professor Andrew Spencer, Head of Malignant Haematology, Stem Cell Transplantation and Head of Myeloma Research at Alfred Health Hospital, Australia to discuss the pivotal role of primary care providers in myeloma detection and precursor management. Stay tuned for more insights on early detection and management. #MultipleMyeloma #Diagnosis

This year we will be attending the APFCB Congress in Sydney. Come and speak to our team to hear more about our latest innovation for monoclonal assessment, the EXENT® System! Register for a live demonstration: https://hubs.li/Q02Td4WZ0 #Innovation #Multiplemyeloma #EXENTSystem

Next week we are flying to Marseille to attend the 21st Biennial Meeting of The European Society for Immunodeficiencies (ESID), 16th - 19th October, an event that will bring together the global PID community. Come and talk to us. We will be at booth 17A. #ESID2024